News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
FDA Delays Decision on Sanofi-Aventis (France)'s Pentacel to November 2
June 11, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PARIS, June 11 (Reuters) - The U.S. Food and Drug Administration has delayed giving a marketing decision on Sanofi-Pasteur's vaccine Pentacel until Nov. 2 from June 8, the French vaccine maker said on Monday, citing technical reasons.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
Sanofi
MORE ON THIS TOPIC
Insights
Beyond equity: Why venture debt is reshaping European biotech
October 8, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Opinion
Opinion: FDA must ensure American patients can access new and experimental drugs
October 5, 2026
·
7 min read
·
Houman David Hemmati
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
October 5, 2026
·
6 min read
·
Jennifer C. Smith-Parker
FDA
US government launches AI-driven programs to overhaul clinical trials
October 1, 2026
·
4 min read
·
Gabrielle Masson